The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency. Prolastin and Prolastin-C are administered intravenously to raise the levels of AAT in the blood and lungs. Prolastin-C delivers twice the active protein per milliliter as Prolastin, cutting infusion volume and time in half when given at the recommended rate. Clinical studies have shown that Prolastin-C and Prolastin are equally effective at raising AAT levels in the blood.
Prolastin and Prolastin-C are indicated for chronic augmentation and maintenance therapy of adults having congenital deficiency of alpha-1 PI AAT with clinically demonstrable panacinar emphysema.
For more information call (800) 243-4154 or visit www.talecris.com.